Passage Bio, Inc. (PASG)
4.52
+0.19
(+4.39%)
USD |
NASDAQ |
Aug 28, 16:00
4.57
+0.05
(+1.11%)
After-Hours: 20:00
Passage Bio Shareholders Equity (Quarterly) : 4.456M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.456M |
| March 31, 2026 | 11.75M |
| December 31, 2025 | 18.76M |
| September 30, 2025 | 31.12M |
| June 30, 2025 | 38.26M |
| March 31, 2025 | 46.71M |
| December 31, 2024 | 61.26M |
| September 30, 2024 | 72.72M |
| June 30, 2024 | 90.56M |
| March 31, 2024 | 104.88M |
| December 31, 2023 | 111.28M |
| September 30, 2023 | 126.28M |
| June 30, 2023 | 150.41M |
| March 31, 2023 | 170.35M |
| December 31, 2022 | 201.37M |
| September 30, 2022 | 224.40M |
| Date | Value |
|---|---|
| June 30, 2022 | 248.05M |
| March 31, 2022 | 281.31M |
| December 31, 2021 | 318.66M |
| September 30, 2021 | 362.23M |
| June 30, 2021 | 402.27M |
| March 31, 2021 | 441.50M |
| December 31, 2020 | 304.71M |
| September 30, 2020 | 338.90M |
| June 30, 2020 | 363.40M |
| March 31, 2020 | 386.67M |
| December 31, 2019 | -56.25M |
| September 30, 2019 | -44.14M |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | -12.17M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ARS Pharmaceuticals, Inc. | 12.51M |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 25.18M |
| Total Liabilities (Quarterly) | 20.72M |
| Current Ratio | 1.215 |
| Net Debt Paydown Yield | 31.99% |